This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 116/3/249    most recent CIRCULATIONAHA.107.694562v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, W. L. Articles by Jaffe, A. S. Search for Related Content PubMed PubMed Citation Articles by Miller, W. L. Articles by Jaffe, A. S. Related Collections Congestive Myocardial cardiomyopathy disease

(Circulation. 2007;116:249-257.)
© 2007 American Heart Association, Inc.

Heart Failure

Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure

The Importance of Change Over Time

Wayne L. Miller, MD, PhD; Karen A. Hartman, BSN, CCRC; Mary F. Burritt, PhD; Diane E. Grill, MSc; Richard J. Rodeheffer, MD; John C. Burnett, Jr, MD; Allan S. Jaffe, MD

From the Division of Cardiovascular Diseases, Department of Medicine (W.L.M., K.A.H., R.J.R., J.C.B., A.S.J.), Department of Laboratory Medicine and Pathology (M.F.B., A.S.J.), and Division of Biostatistics (D.E.G.), Mayo Clinic, Rochester, Minn.

Correspondence to Wayne L. Miller, MD, PhD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail miller.wayne{at}mayo.edu

Received July 13, 2006; accepted April 18, 2007.

Background— Cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) have been used to estimate prognosis in heart failure; however, most studies have evaluated decompensated patients with single measurements. To determine if there are advantages to serial measurements, we evaluated stable chronic heart failure patients every 3 months for 2 years.

Methods and Results— A cohort of 190 New York Heart Association class III–IV heart failure patients was prospectively enrolled from June 2001 to January 2004. Primary end points were death, cardiac transplantation, or hospitalization. At study enrollment cTnT was <0.01 ng/mL in 87 (45.8%) patients, 0.01 to 0.03 ng/mL in 50 (26.3%) patients, and >0.03 ng/mL in 53 (27.9%) patients. An increase in cTnT above normal (<0.01 ng/mL) carried a 3.4-fold increased risk (P=0.019). Further increases (20%) from an elevated level worsened the overall risk (hazard ratio, 5.09; P<0.001). BNP was elevated (>95th percentile for age and gender normal population) in 122 (64.2%) patients. An elevation of BNP from normal at any time during the study was associated with a poor outcome, but, once elevated, further changes in BNP (increases or decreases) remained associated with the same risk (hazard ratio, 5.09; P<0.001). Combined elevations of cTnT (>0.03 ng/mL) and BNP defined the highest risk group (hazard ratio, 8.58; P<0.001).

Conclusions— Elevations of cTnT or BNP from normal detected at any time during clinical follow-up in ambulatory patients with chronic heart failure are highly associated with an increased risk of events. Further increases in cTnT contribute to additional risk. Combined elevations of cTnT and BNP contribute the highest risk. The ability to monitor changes by serial measurements adds substantially to the assessment of risk in this patient population.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				P. Ballo, A. Bocelli, and S. Mondillo Letter by Ballo et al Regarding Article, "Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time" Circulation, January 29, 2008; 117(4): e23 - e23. [Full Text] [PDF]

				W. L. Miller, K. A. Hartman, D. E. Grill, M. F. Burritt, R. J. Rodeheffer, J. C. Burnett Jr, and A. S. Jaffe Response to Letter Regarding Article, "Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time" Circulation, January 29, 2008; 117(4): e24 - e24. [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF]